

Postpartum Haemorrhage and Carboprost for Its Prevention: A Narrative Review

Saloni .¹, Manjusha Agrawal¹

Received 04/27/2024
Review began 05/26/2024
Review ended 06/16/2024
Published 06/21/2024

© Copyright 2024

. et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: 10.7759/cureus.62875

1. Obstetrics and Gynecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND

Corresponding author: Saloni ., dr.saloni16@gmail.com

Abstract

The most frequent and harmful side effect of childbirth is obstetric haemorrhage. Postpartum haemorrhage (PPH) remains the primary cause of maternal mortality worldwide. Most PPH-related deaths take place in the first 24 hours of life. It is commonly believed that prompt diagnosis and treatment could avert the majority of PPH-related deaths. The rapid transition of haemorrhage from the remunerated to the decompensated stage is frequently overlooked. For this reason, anticipation, early detection, and management are crucial to reducing the risk of severe PPH (SPPH) or improving its clinical outcomes. Third-stage labour is a high-risk period for PPH. Active management of PPH is an effective intervention to lessen the incidence of PPH and has been promoted as a means of lowering fatality rates. Currently, prostaglandins (PGs) are advised as a second-line uterotonic medication. Strong uterotonic drugs such as carboprost tromethamine play a physiological role in human parturition, helping to birth the fetus and controlling PPH. Prostaglandins have a major effect on uterine tone, which minimizes blood loss. Their discovery, together with the use of their counterparts as uterotonics, has improved PPH management. In order to assist healthcare professionals in managing PPH promptly and minimizing adverse effects on both the mother and the newborn, this review will describe the causes of the disorder, the strategies that have been tried to treat it, and the role that carboprost plays in preventing it.

Categories: Obstetrics/Gynecology

Keywords: uterotonics, bleeding in pregnancy, active management of third stage of labour, third stage of labour, haemorrhage in pregnancy

Introduction And Background

Pregnancy- and childbirth-related deaths are known as maternal deaths. These deaths are seen as preventable and rank among the major public health issues in developing and impoverished countries. The frequent causes of maternal death are infection, eclampsia, obstructed labour, unsafe abortions, and postpartum haemorrhage (PPH). The loss of blood of more than 500 millilitres (mL) during delivery via the vagina and 1000 mL after caesarean delivery is generally referred to as PPH. However, there are differences in definitions, and the diagnosis of PPH is frequently based on imprecise estimations of blood loss. Furthermore, the usual blood loss during birth often surpasses 500 or 1000 mL, and the normal increases in plasma volume that happen during pregnancy may conceal signs of haemorrhage or shock from blood loss [1,2].

In contemporary obstetrics, routine active management of the third stage of labour (AMTSL) may be crucial in lowering maternal mortality and morbidity from PPH. In order to prevent PPH, uterotonics such as oxytocin, methylergometrine, and 15-(S)-15-methyl PGF₂α are employed. According to studies, there are significant differences in how third-stage labour is managed. It has been demonstrated that uterotonic treatment reduces PPH incidence by 40%. However, there are adverse consequences linked to it, such as pulmonary oedema, myocardial infarction, vomiting, hypertension, and shivering diarrhoea. An intramuscular form of PGF₂α mimic is carboprost (CP) tromethamine [3]. It has been shown to be 84%-96% successful in treating uterine atony-related persistent haemorrhage. But, since its debut, there have been few studies evaluating its efficacy in treating and preventing PPH, and only one particularly looking at its application after caesarean delivery [4].

Review

Epidemiology

According to data from the World Health Organization (WHO), PPH is the most common cause of illness and mortality among mothers worldwide, accounting for 25% of all maternal fatalities. In India, the incidence of PPH is 6% after a C-section and 2%-4% after a vaginal delivery. It is a significant factor in India's 19.9% maternal death rate. Approximately 70,000 maternal deaths occur worldwide every year, predominantly in low- and middle-income nations, as a result of the approximately 14 million women who suffer from PPH. This is the equivalent of one fatality every six minutes. PPH-related deaths are mostly avoidable and have all but disappeared in high-income nations (HICs) [5,6].

How to cite this article

. S, Agrawal M (June 21, 2024) Postpartum Haemorrhage and Carboprost for Its Prevention: A Narrative Review. Cureus 16(6): e62875. DOI 10.7759/cureus.62875

Risk factors for PPH

PPH cases are increasing because of factors such as women's advanced age at childbearing, increased body mass index (BMI), large birth weight, inadequate prenatal care, shortage of trained birth attendants, delayed medical attention seeking, and restricted access to emergency obstetric services [7]. Of the various causes of PPH, uterine atony is the most prevalent. At least 75% of PPH cases and 1 in 40 complicated births in the United States are caused by the uterus not contracting well after delivery. While prolonged labour may result in uterine tiredness or inadequate contractions, which in turn produce postpartum uterine atony, quick labour is thought to be connected with powerful contractions that tire out the uterus. Atony can also be brought on by increased or induced labour, which all contribute to the development of PPH [8]. In many parts of the world, fetal macrosomia (FM), or gestational weight $\geq 4,000$ g, is acknowledged as a risk factor for PPH, being mostly linked to dyslipidaemia, a history of a macrosomic fetus, diabetes, obesity before becoming pregnant, an increase in weight during pregnancy, abnormal fasting and postprandial glucose levels, and post-term pregnancy. The results of the meta-analysis indicated that FM raises the possibility of PPH in expectant mothers. Only three investigations investigated the relationship between severe PPH and FM, and despite significant heterogeneity, the meta-analysis did not find any correlation between both clinical disorders [9].

Genital Tract Trauma

If genital tract injuries are not detected right away, it might result in bleeding and a significant volume of PPH. More than 85% of women who give birth vaginally will experience some perineal trauma, and between 60% and 70% of them will require suturing. To detect any injuries to the cervix, vagina, or perineum, a thorough examination of the genital tract should be carried out. A competent obstetrician should treat upper vaginal or cervical rips since there is a chance that the surrounding structures could be harmed [10]. PPH can be directly caused by coagulation problems. Furthermore, severe bleeding can cause coagulation factors to be consumed, which might worsen dilutional coagulopathy following volume resuscitation and cause PPH to worsen. PPH may result from widespread intravascular coagulopathy, which includes sepsis, amniotic fluid embolism, significant blood loss or transfusion, intrauterine fetal death with protracted retention of a dead fetus, and placental abruption. Excessive blood loss after giving birth is also linked to other coagulation diseases such as thrombocytopenia, von Willebrand disease, and anticoagulant medication [11]. Research has indicated a connection between advanced maternal age and PPH, but there is currently insufficient agreement on this topic. One study found that mothers over 35 years old had a higher chance of developing SPPH [12].

According to Sheen et al., women who are older than 45 years of age are more likely to experience a variety of negative outcomes during their hospital stay after giving birth, including PPH. However, a meta-analysis showed no relationship between maternal age (more than equal to 35) and PPH. Furthermore, another study revealed that growing older has a preventive effect on PPH [13]. Maternal age < 18 years was associated with increased SPPH, although older mother age (≥ 35 y) increased the incidence of severe PPH in univariate analysis, according to the results of another study. The adjusted ratio had a wide confidence interval even though among the patients with SPPH, there was only one woman (0.20%) whose maternal age was less than 18 years; among the controls, it was 0.06% [14].

The risk of severe PPH (SPPH) was 4.94 times higher in women with a history of PPH. Similarly, an Australian study found that 28% of medical audits had recurrences [15]. According to a Swedish study, the recurrence of PPH may be explained by genetic and environmental variables [16]. Consistent with earlier research, women who conceived by IVF had a higher risk of developing SPPH. Placental adherence increased in a group following the use of assisted reproductive technology, according to Tang et al. [17]. According to the study, a C-section was linked to a higher risk of SPPH in the univariate analysis. On the other hand, the multivariate model showed that women who had caesarean deliveries had a 43% lower incidence of SPPH. Most earlier research findings were at odds with the beneficial benefits of C-sections. But as compared to vaginal births, a few studies have found that C-sections protect against PPH. Consistent with earlier research, women who experienced placenta previa, placental abruption, or placenta accreta spectrum (PAS) had a considerably higher risk of SPPH. PPH following blood transfusion and PPH after hysterectomy are examples of severe cases of PPH when placenta-related variables played a key role [18].

Strategies to reduce morbidity and mortality from PPH

PPH primarily manifests during the third stage of labour (TSL), and it can be avoided using AMTSL. Using uterotonics in the TSL before placenta delivery is the most efficient course of action to prevent PPH. The best medication is an injectable uterotonic, although if one is not available, oral misoprostol may be used instead. Initiatives to support anaemia correction may be required, as up to 25% of pregnant women suffer from prenatal anaemia. Some professional associations have released PPH guidelines, which suggest that the therapeutic objective be haemoglobin (Hb) level of more than 8 g/dL. AMTSL is linked to a significant decrease in the incidence of PPH as compared to expectant management [19]. Proactive uterine massage, controlled cord traction (CCT), and prophylactic oxytocin are helpful methods during the TSL. If bleeding occurs and the placenta remains in place, it should be manually removed as quickly as feasible. It is well-recognized that macrosomia causes the uterus to become over-dense, which is linked to uterine atony [20].

Evidence-Based Interventions to Prevent PPH

AMTSL is a term used to describe a series of treatments designed to avoid PPH [21]. AMTSL entails giving all women uterotonic, preferably within one minute of delivery, CCT to promote placental delivery, uterine massage to initiate uterine contraction, and tonus assessment every 15 minutes for the first two hours after delivery to detect uterine atony early [22,23]. The WHO advises that competent birth attendants and medical professionals with pregnancy and delivery management training should perform AMTSL [24].

Trained community health workers or professional providers can apply evidence-based therapies that lower the incidence of PPH and are appropriate for low-resource settings. These are women who give birth without the assistance of a competent clinician using misoprostol or AMTSL. For a long time, uterotonic have been used to treat uterine atony and lessen the amount of blood lost after childbirth. They also cause uterine contractions. One of the most crucial measures to avoid PPH is the use of a uterotonic medication as soon as the baby is delivered. AMTSL comprises three primary steps: delivering the placenta to the uterus with CCT and counter-traction; injecting a uterotonic drug (ideally oxytocin) within a minute of the baby's delivery; and massage of the uterus following placenta delivery, together with uterine palpation to determine whether massage therapy is necessary for the two hours that follow placenta delivery. In the absence of a qualified practitioner who can perform AMTSL, recent WHO guidelines authorize the administration of misoprostol by a health professional trained in its use for the prevention of PPH. Because of their affordability, efficiency, and safety, misoprostol pills are the best option for treating PPH in home births in environments with limited resources [25].

A Cochrane study evaluated the impact of preventive oxytocin administered during the TSL on PPH. A total of 20 randomized controlled trials (RCTs) with 10,806 women were included in the review. When compared to a placebo, prophylactic oxytocin halved the risk of PPH. Compared to ergot alkaloids, it resulted in a 25% lower risk of PPH. When oxytocin and ergometrine were taken together, the risk of PPH was not significantly different from when ergot alkaloids were taken alone. Ergot alkaloids were not as well tolerated as oxytocin [6].

Other Interventions

Uterine massage: There is little to no clear evidence supporting the effectiveness of uterine massage in preventing PPH. Information from two RCTs with 1,491 participants that looked at the advantages of uterine massage before, following, or concurrently with placenta delivery was assessed by a Cochrane review. Regardless of when the massage was started, the intervention and control groups did not significantly differ in the amount of uterine blood lost. When it comes to preventing PPH in women who have received prophylactic oxytocin, the WHO does not advise prolonged uterine massage. For all women, however, it is recommended to detect uterine atony, a failure of the uterus to contract adequately as soon as possible after giving birth [26].

Cord clamping early versus late: A Cochrane analysis evaluated the impact on maternal and newborn outcomes of early versus late cord clamping following delivery. Included in the review were 15 trials with 3,911 mother and child pairs carried out in low- and middle-income countries (LMICs) and high-income countries (HICs). PPH and severe PPH in the mothers did not significantly differ between the early and late cord clamping groups. In contrast, early and late cord clamping enhanced infants' early Hb concentrations and iron reserves; hence, to improve baby outcomes, the WHO recommends late cord clamping [27].

Controlled cord traction: There have been two significant CCT trials, one involving 23,861 women in eight LMICs and the other involving 4,013 women in France. The findings of these trials imply that CCT, when used to control the TSL, has no discernible clinical impact on the prevalence of PPH. The WHO recommends that CCT should be performed by trained birth attendants [28].

Management of PPH

An integrated team effort combining effective communication between an anesthesiologist, a haematologist/blood bank, and an interventional radiologist is necessary for PPH therapy, along with an obstetrician and perinatologist. Precise blood loss evaluation, keeping an eye on maternal symptoms, replenishing fluids, blood, and blood products, and halting the bleeding source all depend on this [29].

Blood Loss Evaluation

Accurate blood loss measurement is crucial for determining the extent of bleeding and evaluating the patient's reaction to bleeding. A reference guide with pictures to aid in the visual computation of blood loss declares that one may estimate blood loss using the following items: a soaked, soiled sanitary towel, a tiny and large soaked swab, and a full kidney dish. On the other hand, misdiagnosis rates in visual estimations range from 35% to 50%. Therefore, since estimated blood loss (EBL) is always extremely difficult and delayed, quantitative testing is recommended instead of EBL [30].

Management Algorithm

In addition to uterotonic, non-surgical methods, such as balloon tamponade, surgical procedures like compression sutures, ovarian-uterine artery ligations, ligation of the iliac artery (Internal), and/or hysterectomy peripartum, can be employed in the management of PPH.

Fluids in Case of Bleeding

When bleeding, it is advised to restore lost extracellular fluid with isotonic crystalloids as soon as possible using a protocol-based approach. Compared to crystalloids, the infusion of colloids results in haemodynamic stabilization with less tissue oedema. In cases of severe bleeding, aggressive volume loading may exacerbate dilutional coagulopathy. Thus, it is crucial to minimize hypervolaemia and dilution of coagulation factors that could worsen coagulopathy by replacing blood with a restricted amount (1-2 mL crystalloid for every 1 mL blood loss) [31].

Carboprost

The potent uterotonic agent PGF₂α plays a physiological role in human parturition, controlling PPH as well as facilitating foetal birth. Since more than three decades ago, CP tromethamine, a more powerful counterpart of 15-(S)-15-methyl PGF₂α, has been in use. This is longer-acting and more effective than natural PGF₂α. Thus, prostaglandins are the class of uterine-stimulating medicines with the fewest adverse effects that are used to manage TSL and avoid postpartum haemorrhage. For treating PPH, it is given intramuscularly every 15 minutes up to a maximum of eight times. More than 10% of women who receive treatment report experiencing the most frequent adverse effects, which include nausea, vomiting, and diarrhoea. Asthmatics must exercise caution since it can result in bronchospasm [32].

Promising results have been found in the few trials that have looked at the effectiveness of a prophylactic dosage of CP in PPH prevention. To AMTSL, intramuscular methyl ergometrine (ME), misoprostol sublingual, and intramuscular CP and ME were studied by Vaid et al. as preventive measures. They discovered that all three medications were equally effective in preventing PPH, although the most common side effect of CP was diarrhoea [33]. Abdel-Aleem et al. evaluated the extent of the TSL and the blood loss (mean) between 150 women treated with CP and ME and found that the former was substantially shorter [34].

According to Sunil Kumar et al.'s research, 97% of patients experienced satisfactory prevention of PPH using CP, a potent uterotonic. Compared to oxytocin, only four patients required additional uterotonic, which caused 21 patients to require extra medication to stop excessive bleeding. When it came to reducing PPH in high-risk patients having C-sections, Bai et al. found that CP was superior to oxytocin in this regard. In their investigation, vomiting was relatively common among patients who got CP [35,36]. When used in a therapeutic dose of 250 µg, CP has been shown to be 84%-66% effective in treating PPH and may prevent the need for surgical procedures. However, people who receive the recommended dosage of CP inevitably experience nausea, vomiting, fever, and asthma. In addition, patients may get heat flashes, perspire, and get agitated. However, at the preventive dose of 125 µg, these side effects are significantly reduced [37].

In a comparative trial of various uterotonics for atonic PPH in high-risk patients, Reddy and Shenoy discovered that the average length of the TSL was 2.44 minutes for the ME group and 2.33 minutes for the CP group. With ME, the mean blood loss was 202±84 mL, while with CP, it was 127±97 mL [38]. In a related study on the impact of uterotonics in AMTSL, Bhattacharya et al. discovered that the group receiving ME had a mean TSL duration of 8.06 minutes, whereas the group receiving CP had a mean duration of 4.8 minutes [39].

The durations for the CP and ME groups in a different study were 2.63 minutes and 3.6 minutes, respectively [40]. In the Singh et al. trial, adverse effects included vomiting (number 1) and diarrhoea (number 1) in two (3%) of the ME group and nausea in eight (12.4%) of the CP group (number 2) [41].

In research on women who had vaginal births after 28 weeks of amenorrhoea and had one or more haemorrhagic risk factors (HRF), the participants were split into two groups: one group received oxytocin alone, and the other received oxytocin along with CP. They discovered that for the HRF of multiparity and uterine overdistension, blood loss was reduced by oxytocin and then CP (p=0.003; p=0.00001). They concluded that in patients with HRF, particularly those with multiparity and uterine overdistension, the synergy of two uterotonics, oxytocin and CP, helps to reduce postpartum bleeding. For parturients at higher risk, adding CP is a good substitute for reducing PPH [42]. When Lamont et al. evaluated the effectiveness of CP and syntometrine (SM) in preventing PPH, they found that both medications prevented PPH as well. Compared to 0.8% of patients who received SM, 21% of patients who took CP experienced diarrhoea. While major adverse effects are rare and self-limited, the previously mentioned potential drawbacks still exist [43].

CP reduces the TSL and reduces blood loss when compared to standard uterotonics; nevertheless, it raises the possibility of diarrhoea, vomiting, and stomach pain. However, CP can bring on bronchospasms. Desaturation of arterial Hb oxygen can be brought on by intrapulmonary shunting in conjunction with

increases in systemic and pulmonary vascular resistance. Individuals with asthma are more vulnerable to these issues, yet some occurrences of bronchospasm in non-asthma individuals have been documented. It is important to remember that PGF2 α is an endogenous substance that has a role in both disease and physiology. Several experimental and clinical investigations have demonstrated the connection between PGF2 α and severe acute or chronic inflammatory diseases, which is an increasing risk factor for diabetes, septic shock, atherosclerosis, and a host of other conditions [44-47]. CP should be administered cautiously in individuals with the aforementioned conditions, particularly if repeated injections are required [48].

CP has a few disadvantages that should be taken into account. Firstly, it is a costly medication. Secondly, not all locations may have the prophylactic dose readily available. Lastly, the drug must be refrigerated between 2-4 °C. It is a costly therapy that needs to be kept cold, making it challenging to use in environments with limited resources.

Conclusions

Even though PPH is one of the primary preventable causes of maternal death, disparities in women's access to healthcare and the kind of care they receive account for the fact that PPH remains the most common cause of maternal death. TSL is when there is the highest risk of PPH due to potential irregular contractions of the uterus following childbirth. AMTSL is a highly effective technique for lowering the death rate of mothers. It provides a significant therapeutic advantage in reducing maternal issues with minimal risk, and it ought to be adopted as routine treatment at a minimal cost. Based on the above-described studies, CP is more effective than oxytocin at preventing PPH in high-risk recipients of CD. However, there were side effects associated with it, and the medication was well taken. For this patient type, CP might be considered a suitable drug for the AMTSL. Programmes to identify and stop early risk factors that could condition the occurrence of PPH and other maternal problems need to be improved and put into action.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Saloni ., Manjusha Agrawal

Acquisition, analysis, or interpretation of data: Saloni ., Manjusha Agrawal

Drafting of the manuscript: Saloni ., Manjusha Agrawal

Critical review of the manuscript for important intellectual content: Saloni ., Manjusha Agrawal

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Leduc D, Senikas V, Lalonde AB, et al.: Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. *J Obstet Gynaecol Can.* 2009, 31:980-93. [10.1016/S1701-2163\(16\)34329-8](https://doi.org/10.1016/S1701-2163(16)34329-8)
2. World Health Organization: WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. World Health Organization, Geneva, Switzerland; 2007.
3. Chelmow D: Postpartum haemorrhage: prevention. *BMJ Clin Evid.* 2011, 2011:1410.
4. Shiva K, Agarwal A: A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. *IOSR J Dent Med Sci.* 2020, 19:1-4.
5. Lifesaving solution dramatically reduces severe bleeding after childbirth . (2023). Accessed: March 18, 2024: <https://www.who.int/news/item/09-05-2023-lifesaving-solution-dramatically-reduces-severe-bleeding-after-childbirth>.
6. Postpartum haemorrhage remains a major challenge in areas with limited access to healthcare facilities . (2023). Accessed: April 25, 2024: <https://www.financialexpress.com/healthcare/news-healthcare/postpartum-haemorrhage-remains-a-major-challenge-in-areas...>
7. Pubu ZM, Bianba ZM, Yang G, et al.: Factors affecting the risk of postpartum hemorrhage in pregnant women in Tibet health facilities. *Med Sci Monit.* 2021, 27:e928568. [10.12659/MSM.928568](https://doi.org/10.12659/MSM.928568)
8. Gill P, Patel A, Van Hook JW: Uterine atony. *StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024.*

9. Quezada-Robles A, Quispe-Sarmiento F, Bendezu-Quispe G, Vargas-Fernández R: Fetal macrosomia and postpartum hemorrhage in Latin American and Caribbean region: systematic review and meta-analysis. *Rev Bras Ginecol Obstet.* 2023, 45:e706-23. [10.1055/s-0043-1772597](https://doi.org/10.1055/s-0043-1772597)
10. Sebghati M, Chandrachan E: An update on the risk factors for and management of obstetric haemorrhage. *Womens Health (Lond).* 2017, 13:34-40. [10.1177/1745505717716860](https://doi.org/10.1177/1745505717716860)
11. de Moreuil C, Mehic D, Nopp S, et al.: Hemostatic biomarkers associated with postpartum hemorrhage: a systematic review and meta-analysis. *Blood Adv.* 2023, 7:5954-67. [10.1182/bloodadvances.2023010143](https://doi.org/10.1182/bloodadvances.2023010143)
12. Shaylor R, Weiniger CF, Austin N, Tzabazis A, Shander A, Goodnough LT, Butwick AJ: National and international guidelines for patient blood management in obstetrics: a qualitative review. *Anesth Analg.* 2017, 124:216-32. [10.1213/ANE.0000000000001473](https://doi.org/10.1213/ANE.0000000000001473)
13. Sheen JJ, Wright JD, Goffman D, et al.: Maternal age and risk for adverse outcomes. *Am J Obstet Gynecol.* 2018, 219:390.e1-15. [10.1016/j.ajog.2018.08.034](https://doi.org/10.1016/j.ajog.2018.08.034)
14. Zheng J, Xiao XH, Zhang Q, Mao LL, Yu M, Xu JP, Wang T: Correlation of placental microbiota with fetal macrosomia and clinical characteristics in mothers and newborns. *Oncotarget.* 2017, 8:82314-25. [10.18632/oncotarget.19319](https://doi.org/10.18632/oncotarget.19319)
15. Ford JB, Algert CS, Kok C, Choy MA, Roberts CL: Hospital data reporting on postpartum hemorrhage: under-estimates recurrence and over-estimates the contribution of uterine atony. *Matern Child Health J.* 2012, 16:1542-8. [10.1007/s10995-011-0919-1](https://doi.org/10.1007/s10995-011-0919-1)
16. Oberg AS, Hernandez-Diaz S, Palmsten K, Almqvist C, Bateman BT: Patterns of recurrence of postpartum hemorrhage in a large population-based cohort. *Am J Obstet Gynecol.* 2014, 210:229.e1-8. [10.1016/j.ajog.2013.10.872](https://doi.org/10.1016/j.ajog.2013.10.872)
17. Tang D, Cheng Y, Feng X, Li X, Coyte PC: The use of IVF/ICSI and risk of postpartum hemorrhage: a retrospective cohort study of 153,765 women in China. *Front Public Health.* 2023, 11:1016457. [10.3389/fpubh.2023.1016457](https://doi.org/10.3389/fpubh.2023.1016457)
18. Liu CN, Yu FB, Xu YZ, et al.: Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. *BMC Pregnancy Childbirth.* 2021, 21:332. [10.1186/s12884-021-03818-1](https://doi.org/10.1186/s12884-021-03818-1)
19. Rossi AC, Mullin P, Prefumo F: Prevention, management, and outcomes of macrosomia: a systematic review of literature and meta-analysis. *Obstet Gynecol Surv.* 2013, 68:702-9. [10.1097/O1.0gx.0000435370.74455.a8](https://doi.org/10.1097/O1.0gx.0000435370.74455.a8)
20. Allen VM, O'Connell CM, Liston RM, Baskett TF: Maternal morbidity associated with cesarean delivery without labor compared with spontaneous onset of labor at term. *Obstet Gynecol.* 2003, 102:477-82. [10.1016/s0029-7844\(03\)00570-2](https://doi.org/10.1016/s0029-7844(03)00570-2)
21. Sheldon WR, Blum J, Vogel JP, Souza JP, Gülmezoglu AM, Winikoff B: Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. *BJOG.* 2014, 121 Suppl 1:5-13. [10.1111/1471-0528.12636](https://doi.org/10.1111/1471-0528.12636)
22. Lalonde A, Daviss BA, Acosta A, Herschderfer K: Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. *Int J Gynaecol Obstet.* 2006, 94:243-53. [10.1016/j.ijgo.2006.04.016](https://doi.org/10.1016/j.ijgo.2006.04.016)
23. Postpartum haemorrhage. Accessed: May 7, 2024. <https://www.who.int/teams/sexual-and-reproductive-health-and-research/areas-of-work/maternal-and-perinatal-health/po...>
24. Sibley LM, Spangler SA, Barry D, Tesfaye S, Desta BF, Gobeze AG: A regional comparison of distribution strategies and women's awareness, receipt, and use of misoprostol to prevent postpartum hemorrhage in rural Amhara and Oromiya regions of Ethiopia. *J Midwifery Womens Health.* 2014, 59 Suppl 1:S75-82. [10.1111/jmwh.12156](https://doi.org/10.1111/jmwh.12156)
25. Lalonde A: Prevention and treatment of postpartum hemorrhage in low-resource settings. *Int J Gynaecol Obstet.* 2012, 117:108-18. [10.1016/j.ijgo.2012.03.001](https://doi.org/10.1016/j.ijgo.2012.03.001)
26. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA: Uterine massage for preventing postpartum haemorrhage. *Cochrane Database Syst Rev.* 2013, 2013:CD006431. [10.1002/14651858.CD006431.pub3](https://doi.org/10.1002/14651858.CD006431.pub3)
27. McDonald SJ, Middleton P, Dowswell T, Morris PS: Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. *Cochrane Database Syst Rev.* 2013, 2013:CD004074. [10.1002/14651858.CD004074.pub3](https://doi.org/10.1002/14651858.CD004074.pub3)
28. Westhoff G, Cotter AM, Tolosa JE: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. *Cochrane Database Syst Rev.* 2013, CD001808. [10.1002/14651858.CD001808.pub2](https://doi.org/10.1002/14651858.CD001808.pub2)
29. Günaydin B: Management of postpartum haemorrhage. *Turk J Anaesthesiol Reanim.* 2022, 50:396-402. [10.5152/TJAR.2022.21438](https://doi.org/10.5152/TJAR.2022.21438)
30. Bose P, Regan F, Paterson-Brown S: Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. *BJOG.* 2006, 113:919-24. [10.1111/j.1471-0528.2006.01018.x](https://doi.org/10.1111/j.1471-0528.2006.01018.x)
31. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al.: Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. First update 2016. *Eur J Anaesthesiol.* 2017, 34:332-95. [10.1097/EJA.0000000000000630](https://doi.org/10.1097/EJA.0000000000000630)
32. Kamalajayaram V, Devi ED: Prophylactic PGF2α for control of postpartum bleeding a comparative study with methyl ergometrine. *J Obstet Gynaecol India.* 1994, 44:393-97.
33. Vaid A, Dadhwal V, Mittal S, Deka D, Misra R, Sharma JB, Vimla N: A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methyl-ergometrine versus intramuscular 15-methyl PGF2alpha in active management of third stage of labor. *Arch Gynecol Obstet.* 2009, 280:893-7. [10.1007/s00404-009-1019-y](https://doi.org/10.1007/s00404-009-1019-y)
34. Abdel-Aleem H, Abol-Oyoun EM, Moustafa SA, Kamel HS, Abdel-Wahab HA: Carboprost trometamol in the management of the third stage of labor. *Int J Gynaecol Obstet.* 1993, 42:247-50. [10.1016/0020-7292\(93\)90219-M](https://doi.org/10.1016/0020-7292(93)90219-M)
35. Sunil Kumar KS, Shyam S, Batakurki P: Carboprost versus oxytocin for active management of third stage of labor: a prospective randomized control study. *J Obstet Gynaecol India.* 2016, 66:229-34. [10.1007/s13224-016-0842-x](https://doi.org/10.1007/s13224-016-0842-x)
36. Bai J, Sun Q, Zhai H: A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. *Exp Ther Med.* 2014, 7:46-50. [10.3892/etm.2013.1379](https://doi.org/10.3892/etm.2013.1379)
37. Buttino L Jr, Garite TJ: The use of 15 methyl F2 alpha prostaglandin (Prostin 15M) for the control of

- postpartum hemorrhage. *Am J Perinatol.* 1986, 3:241-3. [10.1055/s-2007-999875](https://doi.org/10.1055/s-2007-999875)
38. Reddy R, Shenoy JS: Active management of third stage of labour: a comparative study in high risk patients for atonic PPH. *J Obstet Gynecol India.* 2001, 51:44.
 39. Bhattacharya P, Pk D, Jain S, Cr K, Ks R: Prophylactic use of 15(s)15 methyl PGF(2 α) by intramuscular route for control of postpartum bleeding—a comparative trial with methylergometrine. *Acta Obstet Gynecol Scand.* 1988, 67:13-5. [10.1111/aogs.1988.67.s145.13](https://doi.org/10.1111/aogs.1988.67.s145.13)
 40. Purushottam J, Roopa P: Prophylactic intramuscular PGF2 α versus intra-venous methyl ergometrine for prevention of atonic PPH in high risk women. *J Obstet Gynecol India.* 2008, 58:417-20.
 41. Singh N, Singh U: Methylergometrine and carboprost tromethamine prophylaxis for postpartum haemorrhage. *J Obstet Gynecol India.* 2005, 55:325-8.
 42. Eléonore* G-L, Carine H-M, Ramata K-K, Roland SN and A: Contribution of carboprost in the prevention of postpartum haemorrhage in vaginal delivery with haemorrhagic risk factors: experience of the teaching hospital of Angre, Abidjan, Côte D'Ivoire. *J Gynecol Res Rev Rep.* 2023:14.
 43. Lamont RF, Morgan DJ, Logue M, Gordon H: A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage. *Prostaglandins Other Lipid Mediat.* 2001, 66:10. [10.1016/S0090-6980\(01\)00154-X](https://doi.org/10.1016/S0090-6980(01)00154-X)
 44. Yu Y, Lucitt MB, Stubbe J, et al.: Prostaglandin F2 α elevates blood pressure and promotes atherosclerosis. *Proc Natl Acad Sci U S A.* 2009, 106:7985-90. [10.1073/pnas.0811834106](https://doi.org/10.1073/pnas.0811834106)
 45. Helmersson J, Larsson A, Vessby B, Basu S: Active smoking and a history of smoking are associated with enhanced prostaglandin F(2 α), interleukin-6 and F2-isoprostane formation in elderly men. *Atherosclerosis.* 2005, 181:201-7. [10.1016/j.atherosclerosis.2004.11.026](https://doi.org/10.1016/j.atherosclerosis.2004.11.026)
 46. Helmersson J, Vessby B, Larsson A, Basu S: Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. *Circulation.* 2004, 109:1729-34. [10.1161/01.CIR.0000124718.99562.91](https://doi.org/10.1161/01.CIR.0000124718.99562.91)
 47. Ricciotti E, FitzGerald GA: Prostaglandins and inflammation. *Arterioscler Thromb Vasc Biol.* 2011, 31:986-1000. [10.1161/ATVBAHA.110.207449](https://doi.org/10.1161/ATVBAHA.110.207449)
 48. Chen Y, Jiang W, Zhao Y, Sun D, Zhang X, Wu F, Zheng C: Prostaglandins for postpartum hemorrhage: pharmacology, application, and current opinion. *Pharmacology.* 2021, 106:477-87. [10.1159/000516631](https://doi.org/10.1159/000516631)